- Home
- SSSS vs PBYI Comparison
SSSS vs PBYI Comparison
Compare SSSS & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SSSS | PBYI |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.4M | 263.4M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | SSSS | PBYI |
|---|---|---|
| Price | $8.79 | $6.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $10.13 | $7.00 |
| AVG Volume (30 Days) | 163.7K | ★ 478.8K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | ★ 11.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | $4,765.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $3.61 | $9.93 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.21 | $2.58 |
| 52 Week High | $10.34 | $7.68 |
Technical Indicators
Market Signals| Indicator | SSSS | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 40.87 | 42.91 |
| Support Level | $8.30 | $5.57 |
| Resistance Level | $9.34 | $7.25 |
| Average True Range (ATR) | 0.33 | 0.44 |
| MACD | -0.05 | -0.13 |
| Stochastic Oscillator | 27.06 | 26.61 |
Price Performance
Historical ComparisonAbout SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.